

Supplementary Table 1. MRI and biopsy outcomes within 6 months after the initial PSA test according to baseline PSA and Stockholm3 risk categories among men with PSA ≥ 1.5 ng/ml.

	PSA ≥ 3.0 ng/ml (n=209)	PSA above age-specific reference limit (n=119)	Stockholm3 Risk Score $\geq 15\%$ (n=117)
Prebiopsy MRI			
PI-RADS score			
Non-suspicious	4 (1.9%)	4 (3.4%)	3 (2.6%)
3	3 (1.4%)	3 (2.5%)	0 (0.0%)
4	3 (1.4%)	3 (2.5%)	2 (1.7%)
5	1 (0.5%)	1 (0.8%)	1 (0.9%)
Missing	1 (0.5%)	1 (0.8%)	1 (0.9%)
Not performed	197 (94.3%)	107 (89.9%)	110 (94.0%)
Biopsy			
Benign	7 (3.3%)	7 (5.9%)	1 (0.9%)
Prostate cancer			
ISUP 1	5 (2.4%)	5 (4.2%)	5 (4.3%)
ISUP 2–5	7 (3.3%)	7 (5.9%)	6 (5.1%)
Not performed	190 (90.9%)	100 (84.0%)	105 (89.7%)

PSA, prostate-specific antigen; MRI, magnetic resonance imaging; PI-RADS, Prostate Imaging Reporting and Data System; ISUP, International Society of Urological Pathology. Current Finnish guidelines recommend PSA above the age-specific reference limit as a trigger for further investigation. Stockholm3 results were not available to clinicians or patients. Column groups are overlapping and not mutually exclusive.

Supplementary Table 2. Prostate MRI and biopsy frequencies and preceding PSA values during follow-up until prostate cancer diagnosis, death from any cause, or six years after the initial PSA test among men with initial PSA ≥ 1.5 ng/ml.

	All men with initial PSA ≥ 1.5 ng/ml (n=469)	Initial PSA ≥ 3.0 ng/ml (n=209)	Initial PSA above age-specific reference limit (n=119)	Initial Stockholm3 Risk Score $\geq 15\%$ (n=117)
Prostate MRI examinations				
None	363 (77.4%)	135 (64.6%)	60 (50.4%)	85 (72.6%)
One	88 (18.8%)	59 (28.2%)	45 (37.8%)	27 (23.1%)
Two	18 (3.8%)	15 (7.2%)	14 (11.8%)	5 (4.3%)
Subtotal: one or more	106 (22.6%)	74 (35.4%)	59 (49.6%)	32 (27.4%)
Prostate biopsies				
None	367 (78.3%)	132 (63.2%)	60 (50.4%)	69 (59.0%)
One	91 (19.4%)	67 (32.1%)	50 (42.0%)	47 (40.2%)
Two	10 (2.1%)	9 (4.3%)	8 (6.7%)	1 (0.9%)
Three	1 (0.2%)	1 (0.5%)	1 (0.8%)	0 (0.0%)
Subtotal: one or more	102 (21.7%)	77 (36.8%)	59 (49.6%)	48 (41.0%)
PSA, median (IQR), ng/ml				
Before first MRI	6.9 (4.9–8.5)	7.2 (5.7–9.0)	7.3 (6.1–9.0)	7.1 (5.4–8.5)
Before first biopsy	7.3 (5.5–9.7)	7.6 (6.0–9.9)	8.0 (6.4–11.1)	7.5 (5.8–10.1)
Before first MRI or biopsy	6.9 (5.1–8.9)	7.3 (5.7–9.3)	7.6 (6.1–9.9)	7.2 (5.6–9.3)

PSA, prostate-specific antigen; MRI, magnetic resonance imaging. Current Finnish guidelines recommend PSA above the age-specific reference limit as a trigger for further investigation. Stockholm3 results were not available to clinicians or patients. PSA medians were calculated among men who underwent the respective examination and had an available PSA value preceding that examination; therefore, denominators vary across PSA rows and columns. The PSA and Stockholm3 threshold columns are overlapping and not mutually exclusive; the “All men with initial PSA ≥ 1.5 ng/ml” column includes the full follow-up cohort.